Skip to content
Open access

Bioinformatics-Driven Discovery of Aβ-Targeted Therapeutics and Diagnostic Biomarkers for Alzheimer's Disease.

Jan 2026 · BioMed Research International · Vol 2026 1, pp. e8975137 · 0 citations · 36 references
Medicine

TL;DR

Three small molecules, resveratrol, curcumin, and apigenin, demonstrated strong binding affinities for NFKBIA, clarifying the priority candidate gene and feasible strategic directions, which are expected to be translated into practical pathways for precision diagnosis and treatment of AD.

Abstract

The deposition of amyloid-β (Aβ) plaque is widely recognized as one of the core pathological events of Alzheimer's disease (AD). This study focused on uncovering potential diagnostic biomarkers and small-molecule candidates potentially modulating Aβ-associated pathways in AD. Weighted gene coexpression network analysis (WGCNA) and machine learning identified the hub gene. Single-nucleus RNA sequencing (snRNA-seq) identified high-expression cell clusters. We identified potential Aβ-binding small-molecule candidates and calculated their binding affinities using molecular docking techniques. Based on molecular docking, we further evaluated the binding stability and conformational dynamics of the protein-ligand complex through molecular dynamics (MD) simulations. NFKBIA was identified as a hub diagnostic gene. Three small molecules, resveratrol, curcumin, and apigenin, demonstrated strong binding affinities for NFKBIA. These findings clarify the priority candidate gene and feasible strategic directions, which are expected to be translated into practical pathways for precision diagnosis and treatment of AD.

Read PDF

Similar papers

Open access Sep 2026

Identification of Candidate Biomarkers and Signaling Pathways Associated with Alzheimer’s Disease Using Bioinformatics Analysis of Next Generation Sequencing Data and Molecular Docking Studies

The GO and pathway enrichment analysis results revealed that the up regulated genes were mainly enriched in response to stimulus, cytoplasm, small molecule binding and signal transduction, whereas down regulated genes were mainly enriched in multicellular organism development, cell junction, ion binding and cardiac con...

B. Vastrad, Shivaling Pattanashetti, C. Vastrad · 0 citations
Sep 2026

Integrating transcriptomic data to identify calmodulin-related diagnostic biomarkers for Alzheimer's disease

Background Alzheimer's disease (AD) is driven by amyloid-β, tau protein, and neuroinflammation. Calmodulin-mediated calcium signaling centrally links synaptic dysfunction, tauopathy, and inflammation, making it a key mechanistic and therapeutic target. Objective To identify calmodulin-related diagnostic biomarkers for...

Xi'an Wang, Yan-Bin Huang, Jiu-Ru Li · 0 citations
Open access Sep 2026

Identification of Gene Signatures and Molecular Mechanisms Underlying the Comorbidity of Alzheimer’s Disease and Crohn’s Disease Using Machine Learning

Objective Alzheimer’s disease (AD) and Crohn’s disease (CD) both involve inflammation and immune dysregulation, yet the potential molecular mechanisms underlying their comorbidity remain unclear. Methods We integrated transcriptomic data from AD and CD patients and applied differential expression analysis, weighted gen...

Hong-Wei Liu, Zhao-Xu Yin, Zhi-Nan Ye et al. · 0 citations
Open access Sep 2026

Novel Pyrazoline Derivatives as Therapeutic Candidate for Alzheimer’s Disease: An Integrated Network Pharmacology and 3D-QSAR Modelling

Findings highlight APOE, BACE1, and CSF1R as key therapeutic targets as key therapeutic targets and identify compound 2a as a promising multi-target lead candidate for additional experimental validation in AD.

Md. Mainuddin Hossain, Towfika Rahman Singdha, Saifullah Sakib et al. · 0 citations
Open access Sep 2026

Identification of Key Genes and Pathways in Parkinson’s Disease Through Bioinformatics Analysis

Integrative transcriptomics identified conserved central-peripheral signatures in PD and five hub genes are candidate biomarkers/therapeutic targets, offering a systems-level framework for disease mechanisms and independent cohort validation.

Ehsan Lotfi, Arsh Ketabforoush, Fereshteh Azeditehrani et al. · 0 citations
Open access Sep 2026

Mapping the Ligand Binding Landscape of Nurr1 (NR4A2): Computational Characterization of Small-Molecule Interactions in Alzheimer’s Disease Pathway

This project establishes a reproducible computational process for ligand and drug discovery, identifying multiple candidates for Nurr1, which, in the near future, can be put into practical testing grounds for validation and eventually clinical drug design.

Ji-Ya Zhou · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.